You are here

Share:

Product Type

Development Stage

Therapeutic Area

Institutes and Centers

Search Technologies

Showing 1-5 of 5 results found

Cancer Therapeutic Based on Hypoxia Inducible Factor 1 (HIF-1) Inhibitors

Researchers at the National Cancer Institute (NCI) have developed small molecule compounds that inhibit activity of hypoxia inducible factor 1 (HIF-1). The HIF-1 inhibitor compounds are designed around the scaffold of naturally occurring metabolite eudistidine. The invention compounds have demonstrated activity against cancer and malaria in vitro.
  • Therapeutics

Renal Selective Unsaturated Englerin Analogues

Researchers at the National Cancer Institute (NCI) have developed a number of analogs of the natural product englerin A, an inhibitor of renal cancer cell growth. Englerin A is thought to exert its anticancer effects by activating protein kinase C (PKC) theta, and exert cytotoxic effects through activation of transient receptor potential cation (TRPC) channels. The invention englerin analogues provide promising treatment strategies for various cancers, diabetes, and HIV, and other diseases associated with the PKC theta and/or TRPC ion channel proteins. Researchers at the NCI seek licensing and/or co-development research collaborations for englerin A analogue compounds.
  • Therapeutics

siRNA Delivery Using Hexameric Tetrahedral RNA Nanostructures for Gene Silencing

Researchers at the National Cancer Institute (NCI), in collaboration with researchers at the University of California, Santa Barbara (UCSB), developed a tetrahedral-shaped RNA nanoparticle for the delivery of siRNA to activate RNAi. The tetrahedral RNA nanoparticles can contain twelve Dicer substrate RNA duplexes for gene silencing. The NCI seeks parties interested in co-development or licensing of these tetrahedral RNA nanoparticles.
  • Therapeutics